Selexipag denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for selexipag are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Applies Quantity Limits to Selexipag

Selexipag is dosed through a titration protocol under prescriber supervision, meaning the quantity dispensed during titration differs from the maintenance quantity once a therapeutic dose is established. Humana's quantity-limit edits are typically calibrated to the maintenance-phase supply and may not accommodate the titration phase, a dose adjustment, or a legitimate clinical reason to dispense a higher quantity. Denials also occur when a refill is requested before the plan's days-supply threshold is met.

## Why This Denial Is Appealable

A quantity-limit denial is not a determination that the drug is medically unnecessary — it is a utilization-management edit that can be overridden when there is a clinical justification. If the requested quantity reflects active titration, a prescriber-directed dose adjustment, or a supply needed to avoid a dangerous interruption in therapy, those facts support an exception request.

## Your Federal Appeal Rights

• Quantity-limit exception request: File this with your prescriber's clinical justification explaining why the requested quantity is medically necessary for this specific patient at this specific point in their treatment.
• Internal appeal: If the exception is denied, you are entitled to a full internal appeal. Humana must explain which quantity-limit criteria were not met.
• ACA §2719 / External Review: After an adverse internal appeal decision, most plans must offer independent external review. The approximately four-month window begins at the internal denial.
• ERISA §503 (employer plans): Guarantees a full-and-fair review and written explanation of the criteria applied.
• Expedited review: Available if a delay in dispensing would seriously jeopardize your health — particularly relevant during titration, where a gap in therapy may require restarting from a lower dose.

## Appeal Timeline

1. Confirm the exact quantity limit and the quantity requested — get both in writing from Humana. 2. Have your prescriber document the clinical reason for the requested quantity (titration phase, dose adjustment, travel supply, etc.). 3. File the exception or internal appeal with supporting documentation. 4. Request expedited review if therapy interruption poses a clinical risk.

## Documentation to Gather

• Current prescription and prescriber's dosing rationale: A note explaining the titration schedule or dose adjustment and why the requested quantity is appropriate at this stage.
• Therapy history: Documentation of prior selexipag doses, titration dates, and tolerability notes.
• Clinical status: Chart notes reflecting current disease status and the risk of therapy interruption.
• FDA prescribing information: The prescribing label describes the approved titration and dosing approach; confirm the requested quantity is consistent with the labeled regimen.

## Criteria-Mapping Structure

Obtain Humana's quantity-limit policy for selexipag. For each limit criterion, document the specific clinical circumstance that justifies deviation — particularly if titration or a prescriber-directed dose change is involved. Cross-reference with the FDA label's dosing guidance to show the requested quantity is within the bounds of the approved prescribing approach.